STOKE THERAPEUTICS INC (STOK) Fundamental Analysis & Valuation

NASDAQ:STOK • US86150R1077

Current stock price

34.03 USD
-0.9 (-2.58%)
At close:
34.03 USD
0 (0%)
After Hours:

This STOK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. STOK Profitability Analysis

1.1 Basic Checks

  • STOK had negative earnings in the past year.
  • In the past year STOK had a positive cash flow from operations.
  • In the past 5 years STOK always reported negative net income.
  • In the past 5 years STOK reported 4 times negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • STOK has a better Return On Assets (-1.65%) than 86.63% of its industry peers.
  • Looking at the Return On Equity, with a value of -1.95%, STOK belongs to the top of the industry, outperforming 89.15% of the companies in the same industry.
Industry RankSector Rank
ROA -1.65%
ROE -1.95%
ROIC N/A
ROA(3y)-26.75%
ROA(5y)-31.13%
ROE(3y)-35.47%
ROE(5y)-40.1%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for STOK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. STOK Health Analysis

2.1 Basic Checks

  • STOK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for STOK has been increased compared to 1 year ago.
  • Compared to 5 years ago, STOK has more shares outstanding
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 18.11 indicates that STOK is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 18.11, STOK belongs to the top of the industry, outperforming 86.43% of the companies in the same industry.
  • There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 18.11
ROIC/WACCN/A
WACC9.55%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • STOK has a Current Ratio of 5.28. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • STOK has a Current ratio (5.28) which is in line with its industry peers.
  • STOK has a Quick Ratio of 5.28. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • STOK's Quick ratio of 5.28 is in line compared to the rest of the industry. STOK outperforms 57.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. STOK Growth Analysis

3.1 Past

  • STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.62%, which is quite impressive.
  • STOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 404.50%.
  • Measured over the past years, STOK shows a very strong growth in Revenue. The Revenue has been growing by 145.85% on average per year.
EPS 1Y (TTM)97.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.89%
Revenue 1Y (TTM)404.5%
Revenue growth 3Y145.85%
Revenue growth 5YN/A
Sales Q2Q%-93.8%

3.2 Future

  • STOK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 130.86% yearly.
  • Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 23.22% on average per year.
EPS Next Y-8430.74%
EPS Next 2Y-780.9%
EPS Next 3Y-265.67%
EPS Next 5Y130.86%
Revenue Next Year-82.83%
Revenue Next 2Y-44.8%
Revenue Next 3Y-11.59%
Revenue Next 5Y23.22%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

2

4. STOK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for STOK. In the last year negative earnings were reported.
  • Also next year STOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, STOK is valued cheaply inside the industry as 93.02% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 44.82
EV/EBITDA N/A
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as STOK's earnings are expected to decrease with -265.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-780.9%
EPS Next 3Y-265.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STOK Dividend Analysis

5.1 Amount

  • No dividends for STOK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STOK Fundamentals: All Metrics, Ratios and Statistics

STOKE THERAPEUTICS INC

NASDAQ:STOK (4/24/2026, 8:09:44 PM)

After market: 34.03 0 (0%)

34.03

-0.9 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-11
Inst Owners119.12%
Inst Owner Change0.03%
Ins Owners3.86%
Ins Owner Change-2.6%
Market Cap2.01B
Revenue(TTM)184.42M
Net Income(TTM)-6.88M
Analysts87.78
Price Target46 (35.17%)
Short Float %22.58%
Short Ratio16.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.69%
Min EPS beat(2)-33.26%
Max EPS beat(2)-12.12%
EPS beat(4)2
Avg EPS beat(4)134.17%
Min EPS beat(4)-33.26%
Max EPS beat(4)558.67%
EPS beat(8)6
Avg EPS beat(8)80.58%
EPS beat(12)9
Avg EPS beat(12)57.04%
EPS beat(16)12
Avg EPS beat(16)26.92%
Revenue beat(2)1
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-76.63%
Max Revenue beat(2)69.22%
Revenue beat(4)3
Avg Revenue beat(4)429.68%
Min Revenue beat(4)-76.63%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)281.74%
Revenue beat(12)9
Avg Revenue beat(12)179.51%
Revenue beat(16)12
Avg Revenue beat(16)133.58%
PT rev (1m)17.31%
PT rev (3m)26.15%
EPS NQ rev (1m)-8.66%
EPS NQ rev (3m)-6.25%
EPS NY rev (1m)-9.96%
EPS NY rev (3m)-6.85%
Revenue NQ rev (1m)-6%
Revenue NQ rev (3m)9.34%
Revenue NY rev (1m)-3.43%
Revenue NY rev (3m)-5.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.91
P/FCF 44.82
P/OCF 44.16
P/B 5.71
P/tB 5.71
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)0.76
FCFY2.23%
OCF(TTM)0.77
OCFY2.26%
SpS3.12
BVpS5.96
TBVpS5.96
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -1.65%
ROE -1.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 24.35%
ROA(3y)-26.75%
ROA(5y)-31.13%
ROE(3y)-35.47%
ROE(5y)-40.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 37.85%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z 18.11
F-Score6
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)37.54%
Cap/Depr(5y)98.36%
Cap/Sales(3y)6.44%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.89%
EPS Next Y-8430.74%
EPS Next 2Y-780.9%
EPS Next 3Y-265.67%
EPS Next 5Y130.86%
Revenue 1Y (TTM)404.5%
Revenue growth 3Y145.85%
Revenue growth 5YN/A
Sales Q2Q%-93.8%
Revenue Next Year-82.83%
Revenue Next 2Y-44.8%
Revenue Next 3Y-11.59%
Revenue Next 5Y23.22%
EBIT growth 1Y79.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2785.63%
EBIT Next 3Y-139.85%
EBIT Next 5Y126.18%
FCF growth 1Y151.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y152.49%
OCF growth 3YN/A
OCF growth 5YN/A

STOKE THERAPEUTICS INC / STOK Fundamental Analysis FAQ

What is the fundamental rating for STOK stock?

ChartMill assigns a fundamental rating of 4 / 10 to STOK.


Can you provide the valuation status for STOKE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 2 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Overvalued.


What is the profitability of STOK stock?

STOKE THERAPEUTICS INC (STOK) has a profitability rating of 2 / 10.


Can you provide the financial health for STOK stock?

The financial health rating of STOKE THERAPEUTICS INC (STOK) is 7 / 10.